إسرائيل - العربية - Ministry of Health

abic marketing ltd - risedronic acid as sodium 35 mg - tablets - risedronic acid - treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures. treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures. prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis. treatment of osteoporosis in men at high risk of fracture.

إسرائيل - العربية - Ministry of Health

sanofi - aventis israel ltd - risedronic acid as sodium 150 mg - film coated tablets - risedronic acid - treatment of postmenopausal osteoporosis.prevention of postmenopausal osteoporosis.

إسرائيل - العربية - Ministry of Health

abic ltd. - diclofenac sodium 50 mg - suppositories - diclofenac - rheumatoid arthritis, osteoarthritis, low back pain and other acute musculoskeletal .disorders such as periarthritis, tendinitis, tenosynovitis, bursitis, sprains, strains and dislocation, ankylosing spondylitis and acute gout.control of pain and inflammation in orthopedic, dental, and other monor surgery.

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - donepezil hydrochloride 5 mg - tablets - donepezil - treatment of mild to moderately severe alzheimer's dementia.

إسرائيل - العربية - Ministry of Health

salomon,levin & elstein ltd - loteprednol etabonate 5 mg / 1 ml - ophthalmic suspension - loteprednol - lotemax is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to otain an advisable diminution in edema and inflammation. lotemax is less effective than prednisolone acetate 1 % in two 28 day controlled clinical studies in acute anterior uveitis, where 72 % of patients treated with lotemax experienced resolution of anterior chamber cells, compared to 87 % of patients treated with prednisolone acetate 1 % . the incidence of patients with clinically significant increases in iop (> or = 10 mmhg) was 1 % with lotemax adn 6 % with prednisolone acetate 1 %. lotemax should not be used in patients who require a more potent corticosteroid for this indication. lotemax is also indicated for the treatment of po

إسرائيل - العربية - Ministry of Health

pfizer pharmaceuticals israel ltd - latanoprost 50 mcg/ml; timolol as maleate 5 mg/ml - eye drops - other antiglaucoma preparations - reduction of intraocular pressure in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers.